As a urologist caring for women with recurrent urinary tract infections, I am consistently surprised by how few are on vaginal estrogen. The landmark clinical trial demonstrating its benefit was published in The New England Journal of Medicine in 1993, and its findings have been reproduced many times since. Yet three decades later, this treatment remains underused.

Why does this matter? Because vaginal estrogen is not just about UTI prevention. It addresses a cascade of changes that affect quality of life in ways many women have been told are simply "part of getting older."

Estrogen plays a pivotal role in keeping the female urogenital tract healthy. During menopause, estrogen levels decline and many women develop Genitourinary Syndrome of Menopause (GSM).

As estrogen falls, the vaginal tissue becomes thinner, drier, and more fragile. The protective lining of the urethra and bladder opening weakens, making it easier for bacteria to invade and cause a UTI. The clinical picture: more frequent UTIs, more frequent trips to the bathroom, and a higher likelihood of leakage.

The goal isn’t to "balance" pH — it’s to lower it. After menopause, vaginal pH often rises above 5.0. Vaginal estrogen restores it to roughly 3.8–4.5, a range in which harmful bacteria like E. coli struggle to survive. Studies show E. coli is rarely detected once vaginal pH falls below 4.5.

Low pH is the calling card of Lactobacillus, a beneficial bacteria that acts as the first line of defense. In the original Raz trial:

Lactobacillus protects the vagina by producing lactic acid (reinforcing the low-pH environment), generating hydrogen peroxide, and physically colonizing the vaginal epithelium so harmful bacteria cannot adhere.

Estrogen rebuilds the vaginal epithelium and supports urethral maturation, restoring the structural integrity of the tissue closest to the bladder opening. These changes directly reduce the risk of bacteria finding a foothold.

UTI prevention gets most of the attention. But the impact on day-to-day urinary symptoms may matter just as much for quality of life. A 2025 meta-analysis of 17 studies and 2,111 patients found striking reductions:

Vaginal estrogen also restores the health of vaginal tissue itself, reducing dryness and pain with intercourse: symptoms many women accept as an unavoidable feature of menopause. By rebuilding the epithelial layer and restoring natural lubrication, local estrogen therapy reduces both symptoms without the systemic risks of oral hormone therapy.

This is one of the most important questions, especially for women with a personal history of breast cancer, blood clots, or stroke.

Low-dose vaginal estrogen (10 mcg tablet, 7.5 mcg/day ring) results in minimal systemic absorption. Serum estradiol typically remains <20 pg/mL which is within the normal postmenopausal range of 5–20 pg/mL.

Higher-dose vaginal creams (0.2–0.625 mg) can produce more substantial increases, with serum levels ranging from 20–70 pg/mL.

The honest read: low-dose vaginal estrogen does cause a small rise in circulating estrogen, but the rise is unlikely to be clinically meaningful. Higher-dose creams deserve more careful conversation.

You would expect that hormone replacement therapy (HRT) would protect vaginal tissue too. Logically, it should. But research consistently shows it does not.

The Women’s Health Initiative and other studies found that 40–50% of women on systemic oral HRT still reported significant vaginal dryness. The reason: vaginal tissue requires very high local estrogen concentrations to restore its protective function. Premenopausal estradiol peaks at 500–600 pg/mL during the cycle, while women on HRT typically achieve only 100–150 pg/mL systemically.

The vagina needs the local surge, not just the baseline level. Women on HRT should also be applying vaginal estrogen.

There were legitimate historical concerns that estrogen therapy raises the risk of clots and strokes. That risk is almost entirely associated with oral estrogen.

When estrogen is swallowed, it passes through the liver before reaching circulation (first-pass metabolism). The liver responds by producing more clotting factors which is the mechanism behind increased thrombosis risk. Topical and vaginal estrogen bypass the liver entirely and enter the bloodstream directly through skin or mucosa at much lower concentrations.

Vaginal estrogen at standard doses carries no meaningful increase in clot or stroke risk.

Anxiety around any estrogen-containing therapy is understandably heightened in women with a history of breast cancer. This is a conversation that belongs between a patient and her oncologist.

What the evidence shows:

For women where even small changes in circulating estrogen are a clinical concern, I recommend checking estradiol levels using a more sensitive assay called liquid chromatography–mass spectrometry (LC/MS) before and after starting therapy. This provides an objective measurement of any change.

The risk-benefit discussion should be made collaboratively with the treating physician. The goal here is accurate information, not a universal recommendation.

Vaginal estrogen comes in several forms and all of them work. The choice usually comes down to preference and ease of use. Doses are deliberately low; that’s exactly why systemic absorption stays minimal.

You may have a mother, wife, friend who is struggling with recurrent urinary tract infections, please share. This information is worth knowing so they can have a conversation with their physician.

Next week, I’ll cover which supplements actually reduce urinary tract infections — what the evidence supports, what the marketing oversells, and what to skip.

Raz & Stamm, N Engl J Med 1993 · Chen et al., Int Urogynecol J 2021 · Anger et al., J Urol 2022 · Porcari et al., Climacteric 2025 · Rahn et al., Obstet Gynecol 2014 · Pinkerton, N Engl J Med 2020 · Pinkerton et al., Clin Obstet Gynecol 2024 · Crandall et al., JAMA 2023 · ACOG Guideline 2019 · Mitchell et al., JAMA Netw Open 2022 · Mainar et al., Maturitas 2026 · Beste et al., Am J Obstet Gynecol 2025 · McVicker et al., JAMA Oncol 2024 · Clinical Consensus, Obstet Gynecol 2021 · Agrawal et al., Obstet Gynecol 2023 · Gompel & Simcock, Lancet Diabetes Endocrinol 2026 · Hickey et al., Lancet 2024 · NCCN Survivorship Guideline 2026 · NAMS Position Statement, Menopause 2020